These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7408260)

  • 41. [Osteopathy in chronic kidney failure].
    Binswanger U; Fischer J; Schenk R; Merz W
    Dtsch Med Wochenschr; 1971 Dec; 96(49):1914-5 passim. PubMed ID: 5127025
    [No Abstract]   [Full Text] [Related]  

  • 42. [Study of serum ionized calcium and immunoreactive parathyroid hormone in patients with renal disorders].
    Chen HJ; Lai YH; Su YH; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1985 Mar; 1(3):188-94. PubMed ID: 3871031
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunoreactive parathyroid hormone in early and advanced renal failure.
    von Lilienfeld-Toal H; Gerlach I; Klehr HU; Issa S; Keck E
    Nephron; 1982; 31(2):116-22. PubMed ID: 7121653
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Radiological, biochemical and clinical aspects of uremic osteopathy in patients with long term dialysis].
    Frey FJ; Jonutis AJ; Bergstein Z; Hodler J; Flury W
    Schweiz Med Wochenschr; 1976 Oct; 106(42):1438-46. PubMed ID: 1006271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of higher prevalence of pancreatic disease with excess parathyroid hormone in uremia.
    Avram MM
    Trans Am Soc Artif Intern Organs; 1980; 26():372-4. PubMed ID: 7245516
    [No Abstract]   [Full Text] [Related]  

  • 46. Famotidine reduces serum parathyroid hormone levels in uremic patients.
    Arik N; Arinsoy T; Sayín M; Taşdemir I; Yasavul U; Turgan C; Caglar S
    Nephron; 1991; 59(2):333. PubMed ID: 1956503
    [No Abstract]   [Full Text] [Related]  

  • 47. Failure to detect an effect of bilateral nephrectomy (NPX) upon parathyroid hormone (PTH) levels in azotemic human subjects.
    Hattner RS; Johnson JW; Bernstein DS; Hampers CL
    J Clin Endocrinol Metab; 1970 May; 30(5):677-9. PubMed ID: 5444557
    [No Abstract]   [Full Text] [Related]  

  • 48. Long-term renal, endocrine, and hematologic evaluation of kidney donors.
    Gonzalez R; Butt KM; Sumrani N; Tejani A
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1946-8. PubMed ID: 2652635
    [No Abstract]   [Full Text] [Related]  

  • 49. [Long-term persistent hypocalcemia in a hemodialysis patient-- pathogenesis of secondary hyperparathyroidism].
    Kitoh C; Kurauchi K; Fujiwara R
    Nihon Jinzo Gakkai Shi; 1983 Aug; 25(8):1011-6. PubMed ID: 6668742
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of cimetidine on serum carboxyl and aminoterminal fragments of parathyroid hormone in chronic uraemic patients.
    Dupont P; Carlier B; Marchetti M; Ducobu J; Van der Donckt C
    Acta Endocrinol (Copenh); 1984 Jan; 105(1):66-71. PubMed ID: 6695546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of aminosteril on serum parathyroid hormone levels in hemodialysis patients.
    Boran M; Cetin S
    Nephron; 1999; 82(1):75-6. PubMed ID: 10224489
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparative effects of dialysis with cuprophan versus polyacrylonitrile membranes on plasma immunoreactive parathyroid hormone levels in patients on chronic hemodialysis.
    Gueris J; Fournier A; Sebert JL; De Fremont JF; Ferriere C; Covoet B; Quichaud J
    Calcif Tissue Res; 1977 May; 22 Suppl():434-8. PubMed ID: 912564
    [No Abstract]   [Full Text] [Related]  

  • 53. Uremic syndrome in man: new evidence for parathormone as a multisystem neurotoxin.
    Avram MM; Iancu M; Morrow P; Feinfeld D; Huatuco A
    Clin Nephrol; 1979 Feb; 11(2):59-62. PubMed ID: 455810
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical and metabolic effects of long-term treatment with 25(OH)D3 in hemodialysis.
    Coratelli P; Petrarulo F; Giannattasio M; Buongiorno E; Passavanti G; Antonelli G; Capurso A; Ferrannini E; Amerio A
    Contrib Nephrol; 1985; 49():20-31. PubMed ID: 3830567
    [No Abstract]   [Full Text] [Related]  

  • 55. Uremic neuropathy: clinical and neurophysiological investigation of dialysis patients using different chemical membranes.
    Violante F; Lorenzi S; Fusello M
    Eur Neurol; 1985; 24(6):398-404. PubMed ID: 4065159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Uremic neuropathies. Comparative study of the velocity of motor and nerve conduction during predialysis, hemodialysis and postransplantation periods].
    Fernández González F
    Arch Neurobiol (Madr); 1976; 39(1):15-36. PubMed ID: 776116
    [No Abstract]   [Full Text] [Related]  

  • 57. A clinical correlative study of bone densitometric changes in hemodialysis patients with hyperparathyroidism.
    Adam B; Arik N; Başoğlu T; Akpolat T; Sahin M; Coşkun C; Kandemir T; Bernay I
    Nephron; 1996; 74(2):483-4. PubMed ID: 8893202
    [No Abstract]   [Full Text] [Related]  

  • 58. [Influence of hemodialysis on the concentration of parathyroid hormone in acute kidney failure].
    Kotot F; Kuska J
    Z Gesamte Inn Med; 1974 Nov; 29(22):916-9. PubMed ID: 4462346
    [No Abstract]   [Full Text] [Related]  

  • 59. Neuropathy and short time haemodialysis (STH).
    Graefe U; Steinhausen D; Langer K; Alterhoff G; Knoll O; Loew H
    Proc Eur Dial Transplant Assoc; 1979; 16():729-30. PubMed ID: 549024
    [No Abstract]   [Full Text] [Related]  

  • 60. Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium.
    Nilsson P; Johansson SG; Danielson BG
    Nephron; 1984; 37(1):25-9. PubMed ID: 6717701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.